» Articles » PMID: 10712338

Influence of Body Weight on the Severity of Dyspnea in Chronic Obstructive Pulmonary Disease

Overview
Specialty Critical Care
Date 2000 Mar 11
PMID 10712338
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

A substantial number of patients with COPD are underweight (UW); they comprise the clinical subtype of "dyspneic" or emphysematous. To determine whether these patients are more dyspneic than normal weight (NW) patients with COPD, we quantitated the severity of dyspnea, using a modified Medical Research Council (MRC) dyspnea scale, in 33 UW and 57 NW patients and compared their pulmonary function tests (PFTs), arterial blood gases (ABGs), and respiratory muscle strength as estimated by maximum static inspiratory (PI(max)) and expiratory (PE(max)) mouth pressures (all as means +/- SEM). Body mass index was 18.7 +/- 1.2 and 24.5 +/- 1.8 kg/m(2) in UW and NW patients, respectively (p < 0.0001). The MRC dyspnea scale was 3. 1 +/- 0.9 in UW and 2.5 +/- 1.2 in NW groups (p = 0.035). All PFT and ABG parameters were similar in the two groups except for DCO (36 +/- 11% in UW and 57 +/- 17% in NW, p < 0.001) and PI(max) (55 +/- 18 mm Hg in UW and 66 +/- 19 mm Hg in NW, p = 0.020). In a stepwise multiple regression model, %DCO and %MVV combined were the best predictors of dyspnea severity (R(2) = 0.30, p = 0.001). We conclude that UW patients with COPD are more dyspneic than NW patients. Although the origin of dyspnea in COPD is multifactorial, changes in DCO and respiratory muscle strength may contribute to its intensity.

Citing Articles

Computed Tomography Registration-Derived Regional Ventilation Indices Compared to Global Lung Function Parameters in Patients With COPD.

Cohen J, Shekarnabi M, Destors M, Tamisier R, Bouzon S, Orkisz M Front Physiol. 2022; 13:862186.

PMID: 35721545 PMC: 9202420. DOI: 10.3389/fphys.2022.862186.


Diaphragm Dysfunction and Rehabilitation Strategy in Patients With Chronic Obstructive Pulmonary Disease.

Cao Y, Li P, Wang Y, Liu X, Wu W Front Physiol. 2022; 13:872277.

PMID: 35586711 PMC: 9108326. DOI: 10.3389/fphys.2022.872277.


Elevated serum Activin A in chronic obstructive pulmonary disease with skeletal muscle wasting.

Zhou G, Gui X, Chen R, Fu X, Ji X, Ding H Clinics (Sao Paulo). 2019; 74:e981.

PMID: 31271588 PMC: 6585865. DOI: 10.6061/clinics/2019/e981.


Recombinant club cell protein 16 (CC16) ameliorates cigarette smoke‑induced lung inflammation in a murine disease model of COPD.

Pang M, Liu H, Li T, Wang D, Hu X, Zhang X Mol Med Rep. 2018; 18(2):2198-2206.

PMID: 29956762 PMC: 6072201. DOI: 10.3892/mmr.2018.9216.


Persistent disabling breathlessness in chronic obstructive pulmonary disease.

Sundh J, Ekstrom M Int J Chron Obstruct Pulmon Dis. 2016; 11:2805-2812.

PMID: 27877034 PMC: 5108478. DOI: 10.2147/COPD.S119992.